Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rimonabant + paracetamol is a hypothetical or research combination of two small molecule drugs, each with distinct mechanisms of action. Rimonabant is an anorectic anti-obesity drug that acts as an inverse agonist at the cannabinoid CB1 receptor and also antagonizes the μ-opioid receptor. It was developed for weight loss and metabolic syndrome but withdrawn due to psychiatric side effects[1][2][5]. Paracetamol (also known as acetaminophen) is a widely used analgesic and antipyretic agent, whose mechanism involves central inhibition of prostaglandin synthesis and modulation of endocannabinoid signaling pathways[3][4]. There are no approved pharmaceutical products or clinical evidence supporting the use of this specific combination in medical practice.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rimonabant + paracetamol.